Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nizar N Zein, MD
The Cleveland Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cedars-Sinai Medical Center, Center for Liver Disease and Transplantation
Los Angeles, California, United States
- Advanced Medical Research Center
Port Orange, Florida, United States
- University of Louisville
Louisville, Kentucky, United States
- Case Medical Center
Cleveland, Ohio, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- the Liver Institute at Methodist Dallas
Dallas, Texas, United States
- Brooke Army Medical Center
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2007
- Primary completion
- 31 May 2012
- Completion
- 31 May 2012
- Last update posted
- 13 Sept 2017
- Registered enrollment
- 146
- Registry id
- NCT00512278
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.